Company to Host Conference Call and Live Webcast on Tuesday, June 25,
2019 at 1:30 p.m. Pacific Time/4:30 p.m. Eastern Time
HAYWARD, Calif.--(BUSINESS WIRE)--
Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage biopharmaceutical
company focused on creating innovative cancer therapies, today announced
that the Company will host a conference call and live webcast on
Tuesday, June 25, 2019, at 1:30 p.m. Pacific Time/4:30 p.m. Eastern Time
to provide a mid-year update on its clinical and preclinical programs.
Investors interested in listening to the conference call may do so by
dialing (866) 211-3164 in the U.S. or (647) 689-6573 internationally,
using Conference ID: 7163128.
To access the live webcast and accompanying slide presentation, please
visit the “Investors” section of the Arcus website at www.arcusbio.com.
Following the live webcast, a replay will be available on the Company’s
website for approximately 30 days.
About Arcus Biosciences
Arcus Biosciences is a clinical-stage biopharmaceutical company focused
on creating innovative cancer therapies. Arcus has several programs
targeting important oncology/immuno-oncology pathways, including a dual
adenosine receptor antagonist, AB928, which is in a Phase 1/1b program
to evaluate AB928 in combination with other agents in multiple tumor
types, and an anti-PD-1 antibody, AB122, which is being evaluated in a
Phase 1 trial and is being tested in combination with Arcus’s other
product candidates. Arcus’s other programs include AB154, an anti-TIGIT
antibody, which is being evaluated in a Phase 1 trial as monotherapy and
in combination with AB122, and AB680, a small-molecule inhibitor of
CD73, which is in a Phase 1 healthy volunteer study. Arcus has extensive
in-house expertise in medicinal chemistry, oncology, immunology,
biochemistry, pharmacology and structural biology. Utilizing these
unique capabilities, Arcus has developed a robust and active early stage
discovery effort focused on small-molecule pipeline expansion. For more
information about Arcus Biosciences, please visit www.arcusbio.com.
View source version on businesswire.com:
https://www.businesswire.com/news/home/20190611005782/en/
Katherine Bock
(510) 694-6231
kbock@arcusbio.com
Nicole Arndt
(510) 284-4728
narndt@arcusbio.com
Source: Arcus Biosciences